Current Research in Translational Medicine最新文献

{"title":"HLA molecules: Another challenge for CAR T cell therapy","authors":"Ikram Salih ,&nbsp;Meryem Fakhkhari ,&nbsp;Hicham Berrougui ,&nbsp;Abdelouahed Khalil ,&nbsp;Karim Benabdellah ,&nbsp;Erden Atilla ,&nbsp;Khalid Sadki","doi":"10.1016/j.retram.2025.103547","DOIUrl":"10.1016/j.retram.2025.103547","url":null,"abstract":"<div><div>CAR-T cell therapy marks a groundbreaking advancement in the treatment of hematological malignancies, demonstrating significant potential to induce durable remissions. However, several limitations hinder its effectiveness, including antigen loss, immune evasion, and hostile tumor microenvironment. The interplay between CAR-T cell therapy and HLA molecules, particularly HLA-DR and HLA-G, emphasises critical challenges to achieving sustained therapeutic success. Monocytes with low or negative HLA-DR expression and high HLA-G presence contribute to immune evasion and reduced CAR-T cell effectiveness. Additionally, genetic variations in HLA influence susceptibility to hematological malignancies and disease progression. Therapeutic strategies to regulate HLA expression and function are crucial to overcome these obstacles. Approaches such as blocking HLA-G, enhancing HLA-DR expression, and optimising HLA profiles in patients by gene editing can improve outcomes of CAR-T cell therapy. Continued research on HLA-mediated immune modulation will improve these strategies and advance CAR-T cell therapy.</div></div>","PeriodicalId":54260,"journal":{"name":"Current Research in Translational Medicine","volume":"73 4","pages":"Article 103547"},"PeriodicalIF":3.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145294405","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Successful treatment of congenital sideroblastic anemia with low-dose decitabine in a patient with NDUFB11 gene mutation (c.276_278del): A case report","authors":"Juan Wang ,&nbsp;Heng Li ,&nbsp;Nan Lv ,&nbsp;Min Wang ,&nbsp;Hongyu Zhao","doi":"10.1016/j.retram.2025.103542","DOIUrl":"10.1016/j.retram.2025.103542","url":null,"abstract":"<div><h3>Background</h3><div>Congenital sideroblastic anemias (CSAs) are an inherited group of blood disorders due to defects of mitochondrial proteins. The <em>NDUFB11</em> gene is essential for the assembly of mitochondrial complex Ⅰ protein. Mutations in the <em>NDUFB11</em> gene can cause sideroblastic anemia with hyperlacticemia, microphthalmia, cardiomyopathy and encephalomyopathy with limited therapeutic options.</div></div><div><h3>Case presentation</h3><div>We reported a 35-year-old man with congenital sideroblastic anemia, skeletal dysplasias and hyperlacticemia. The skeletal muscle stains indicated probability of mitochondrial disorders. By whole-exome sequencing, we identified a mutation (c.276_278delCTT) in <em>NDUFB11</em> gene in this patient which was inherited from his mother. He was unresponsive to the treatment of vitamin B2, vitamin B6, Coenzyme Q10, idebenone, or EPO but achieved hemoglobin concentration rise, transfusion independence and improvement of quality life after treated with low dose decitabine.</div></div><div><h3>Conclusions</h3><div>We proposed that epigenetic factors might play a role in pathogenesis in patients with c.276_278del (p.F93del) mutation in <em>NDUFB11</em> gene and low dose decitabine may be a novel treatment in CSA patients with c.276_278del (p.F93del) mutation in <em>NDUFB11</em> gene.</div></div>","PeriodicalId":54260,"journal":{"name":"Current Research in Translational Medicine","volume":"73 4","pages":"Article 103542"},"PeriodicalIF":3.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145157109","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Optimized GMP-grade Wharton’s jelly’s mesenchymal stromal cells manufacturing and administration protocol for Graft versus Host disease prevention","authors":"Cécile Pochon ,&nbsp;Romain Perouf ,&nbsp;Anne-Béatrice Notarantonio ,&nbsp;Allan Bertrand ,&nbsp;Naceur Charif ,&nbsp;De Carvalho Bittencourt Marcelo ,&nbsp;Guillemette Fouquet ,&nbsp;Ghislaine Cauchois ,&nbsp;Danièle Bensoussan ,&nbsp;David Moulin ,&nbsp;Simona Pagliuca ,&nbsp;Natalia de Isla ,&nbsp;Hervé Sartelet ,&nbsp;Maud D’Aveni ,&nbsp;Marie-Thérèse Rubio","doi":"10.1016/j.retram.2025.103543","DOIUrl":"10.1016/j.retram.2025.103543","url":null,"abstract":"<div><h3>Background</h3><div>Wharton's jelly mesenchymal stromal cells (WJ-MSCs) are multipotent cells derived from the umbilical cord with immunomodulatory properties, making them a promising candidate for cell-based therapies targeting immune-related diseases. Herein, we aim to optimize the conditions of use of clinical-grade WJ-MSCs manufactured according to Good Manufacturing Practice (GMP) for the prevention of graft versus host disease (GVHD) in a preclinical xenogeneic GVHD mouse model.</div></div><div><h3>Methods</h3><div>GMP-compliant WJ-MSCs were primed with IFN-γ and assessed <em>in vitro</em> for their immunosuppressive capacity using coculture assays with activated human T cells. To evaluate <em>in vivo</em> efficacy, NSG mice were sub-lethally irradiated (2 Gy) and transplanted with human peripheral mononuclear cells, then treated with one or more injections of IFN-γ-primed or unprimed WJ-MSCs, to assess xeno- GVHD and its severity.</div></div><div><h3>Results</h3><div>GMP-produced WJ-MSCs suppressed T-cell proliferation <em>in vitro</em> and IFN-γ priming enhanced this effect, largely through Indoleamine 2,3-dioxygenase (IDO) activity<em>. In vivo</em>, three weekly injections of IFN-γ-primed WJ-MSCs significantly improved survival and reduced histological GVHD scores in the liver and skin of recipient mice.</div></div><div><h3>Conclusion</h3><div>These findings demonstrate that IFN-γ-primed GMP-grade WJ-MSCs effectively prevent GVHD in preclinical models, and support their use in optimized dosing regimens for future clinical testing. Given their enhanced immunosuppressive efficacy, they also hold promise as a therapeutic option for established and treatment-refractory forms of GVHD.</div></div>","PeriodicalId":54260,"journal":{"name":"Current Research in Translational Medicine","volume":"73 4","pages":"Article 103543"},"PeriodicalIF":3.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145060642","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The immunobiological functions and therapeutic applications of interleukin-17 family in cancer","authors":"Nasrin Mansuri ,&nbsp;Asma'a H. Mohamed ,&nbsp;Marya Ahsan ,&nbsp;Sana Abdul-Jabbar Ali ,&nbsp;Mohammed Ansar Qureshi ,&nbsp;Waleed A Aldhaaban ,&nbsp;Ayaz Khurram Mallick ,&nbsp;Muataz Elsiddig Dafaalla Mohammed ,&nbsp;Fuzail Ahmad ,&nbsp;Irshad Ahmad ,&nbsp;Mohammad Chand Jamali ,&nbsp;Alaa Shafie","doi":"10.1016/j.retram.2025.103527","DOIUrl":"10.1016/j.retram.2025.103527","url":null,"abstract":"<div><div>Interleukin-17 (IL-17) family cytokines play a pivotal role in immune responses and inflammatory processes, significantly impacting various physiological and pathological conditions. This review explores the immunobiological functions of IL-17, focusing on its diverse cellular sources, including T helper 17 (Th17) cells, γδ T cells, innate lymphoid cells (ILCs), neutrophils, and natural killer T (NKT) cells, and signaling pathways. Special attention is given to IL-17 involvement in cancer, where it exhibits both pro-tumorigenic and anti-tumorigenic effects, influencing tumor proliferation, angiogenesis, metastasis, and drug resistance through various signaling cascades such as JAK/STAT, NF-κB, and PI3K/AKT. Understanding these mechanisms highlights IL-17 as a potential therapeutic target for modulating immune responses and improving cancer treatments.</div></div>","PeriodicalId":54260,"journal":{"name":"Current Research in Translational Medicine","volume":"73 4","pages":"Article 103527"},"PeriodicalIF":3.2,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144596144","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CC486 as a safe and effective bridge to transplant in MDS-del5q with transfusion-dependent anemia following lenalidomide relapse: A case report","authors":"G. Scorpio ,&nbsp;A. Francesio ,&nbsp;S. Piemontese ,&nbsp;A. Acerbis ,&nbsp;S. Mastaglio ,&nbsp;F. Giglio ,&nbsp;G.M. Bergonzi ,&nbsp;L. Lazzari ,&nbsp;A. Ruggeri ,&nbsp;A. Bruno ,&nbsp;S. Marktel ,&nbsp;M.T. Lupo-Stanghellini ,&nbsp;A. Assanelli ,&nbsp;M. Bernardi ,&nbsp;L. Vago ,&nbsp;F. Ciceri ,&nbsp;E. Diral","doi":"10.1016/j.retram.2025.103528","DOIUrl":"10.1016/j.retram.2025.103528","url":null,"abstract":"","PeriodicalId":54260,"journal":{"name":"Current Research in Translational Medicine","volume":"73 4","pages":"Article 103528"},"PeriodicalIF":3.2,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144679457","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Revolutionizing pediatric gene and cell therapy: The hope for lipid-based nanoparticles in blood disorders","authors":"Fatemeh Zahedipour ,&nbsp;Tahereh Mohammadian Gol ,&nbsp;Silas Wisser ,&nbsp;Anjana Ramesh ,&nbsp;Guillermo Ureña-Bailén ,&nbsp;Mahmoud Reza Jaafari ,&nbsp;Markus Mezger","doi":"10.1016/j.retram.2025.103545","DOIUrl":"10.1016/j.retram.2025.103545","url":null,"abstract":"<div><div>The rapidly advancing field of lipid-based nanoparticles (LNPs) as delivery systems for nucleic acids has the potential to revolutionize treatment strategies. LNPs have demonstrated exceptional versatility in delivering genetic material and therapeutic agents to target cells. In gene and cell therapy, LNPs could serve as efficient carriers for introducing genetic materials into the cells, addressing inherited genetic disorders at their root. Their minimal toxicity and immune response make them particularly suitable for pediatric applications. Additionally, the scalability and cost-effectiveness of LNP production offer practical advantages over methods such as viral vectors and electroporation (EP), improving accessibility to advanced therapies for children worldwide. In 2018, the first FDA-approved LNP-based siRNA therapy (Patisiran/ Onpattro®) for treating hereditary amyloidosis brought attention to the feasibility of LNPs for gene therapy. Eventually, authorization and approval of the mRNA-LNP vaccines against COVID-19 (Comirnaty® of BioNTech/Pfizer and SpikeVax® of Moderna) was another milestone for the development of LNP-based nucleic acid therapies. Later, LNPs were applied successfully for the delivery of pDNA, mRNA and siRNA in many types of genetic disorders and cancers. This innovative approach offers a brighter future for pediatric healthcare, where children can look forward to healthier and more fulfilling lives. This review paper provides an overview of the applications of LNPs in gene and cell therapies with a special focus on their pre-clinical application in primary cells, including natural killer cells, T cells, and hematopoietic stem cells, highlighting LNPs’ efficacy, safety profile, and potential for transforming the landscape of pediatric healthcare in the future.</div></div>","PeriodicalId":54260,"journal":{"name":"Current Research in Translational Medicine","volume":"73 4","pages":"Article 103545"},"PeriodicalIF":3.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145265382","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Italian expert consensus recommendations for the safe administration of high-dose methotrexate in children with cancer and for the use of glucarpidase to manage delayed methotrexate elimination and/or high-dose methotrexate-induced acute kidney injury","authors":"Nicolò Peccatori ,&nbsp;Gianluigi Ardissino ,&nbsp;Simone Cesaro ,&nbsp;Romano Danesi ,&nbsp;Stefania Gaspari ,&nbsp;Cristina Meazza ,&nbsp;Rossella Mura ,&nbsp;Carmelo Rizzari","doi":"10.1016/j.retram.2025.103551","DOIUrl":"10.1016/j.retram.2025.103551","url":null,"abstract":"<div><h3>Background</h3><div>High-dose methotrexate (HD-MTX) is used to treat various malignancies in adults and children. However, HD-MTX can lead to severe toxicity, which can require the use of glucarpidase, a recombinant enzyme that rapidly reduces MTX concentrations. Current guidelines, approximated from both adult and pediatric studies and established prescribing indications, do not provide detailed recommendations tailored to children to guide glucarpidase use in clinical practice.</div></div><div><h3>Methods</h3><div>The current study used modified Delphi methodology to develop expert consensus recommendations for the safe administration of HD-MTX, and management of delayed MTX elimination (DME) and/or HD-MTX–induced acute kidney injury (AKI) in children with cancer. Consensus statements were developed by a multidisciplinary Scientific Board of eight Italian physicians, then circulated to an expert panel of 20 pediatric hemato-oncologists for voting. Expert panel members rated their level of agreement using a 5-point Likert scale; consensus was reached if ≥66.6 % of respondents indicated that they “agreed” or “strongly agreed” with each statement.</div></div><div><h3>Results</h3><div>Of the 46 statements, 40 achieved consensus. Clinicians agreed that harmonized glucarpidase treatment guidelines are needed. Careful risk assessment performed by a multidisciplinary team should be established to ensure correct management of pediatric patients on relevant factors such as concomitant medications, monitoring of plasma MTX levels for DME, collection and processing of blood samples, monitoring of renal function for AKI prevention or management, and prompt availability of glucarpidase.</div></div><div><h3>Conclusions</h3><div>These expert consensus recommendations will help pediatric hemato-oncologists to better deal with the various aspects associated with managing HD-MTX in general and with DME or AKI in particular.</div></div>","PeriodicalId":54260,"journal":{"name":"Current Research in Translational Medicine","volume":"73 4","pages":"Article 103551"},"PeriodicalIF":3.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145574893","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Could adherence to SAMPL Guidelines improve statistical reporting in clinical manuscripts? Insights from 150 editorial reviews for specialty journals","authors":"Michal Ordak","doi":"10.1016/j.retram.2025.103536","DOIUrl":"10.1016/j.retram.2025.103536","url":null,"abstract":"<div><h3>Background</h3><div>Although statistical reporting guidelines such as SAMPL (Statistical Analyses and Methods in the Published Literature) exist, statistical errors remain common in biomedical manuscripts. This study investigates whether early author adherence to SAMPL can reduce the need for statistical revision and offers recommendations for broader editorial implementation.</div></div><div><h3>Methods</h3><div>A retrospective analysis was conducted on 150 statistical reviews performed by the author between 2020 and 2025 for clinical medicine journals. Each manuscript was assessed for adherence to key SAMPL principles, including clarity of statistical methods, reporting of assumptions, and presentation of descriptive data. Outcomes were categorized as acceptance, revision (major/minor), or rejection.</div></div><div><h3>Results</h3><div>Of the 150 manuscripts, 99 (66 %) were accepted following SAMPL-based revisions: 87 after one round and 12 after two rounds (<em>p</em> &lt; 0.001). The remaining 51 (34 %) were rejected, primarily due to issues such as inappropriate test use or lack of methodological justification. Among 39 manuscripts with conflicting reviewer opinions, SAMPL-based review helped resolve ambiguity, resulting in 25 rejections and 14 acceptances (<em>p</em> = 0.02). Of the accepted manuscripts, 65 % required major revisions and 35 % minor revisions (<em>p</em> = 0.004).</div></div><div><h3>Conclusion</h3><div>Proactive adherence to the SAMPL Guidelines may reduce editorial workload, improve clarity, and lower preventable rejections. Integrating structured reporting standards into submission processes could enhance transparency and consistency in statistical reporting. These findings support the use of SAMPL-based checklists to improve manuscript quality and streamline peer review.</div></div>","PeriodicalId":54260,"journal":{"name":"Current Research in Translational Medicine","volume":"73 4","pages":"Article 103536"},"PeriodicalIF":3.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144879311","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Green solvent-based synthesis of diclofenac diethylamine-loaded PCL nanoparticles for sustained drug delivery","authors":"Soolafa Al Soliman ,&nbsp;Zaki Ali Ajji ,&nbsp;Antoun Al-Laham","doi":"10.1016/j.retram.2025.103529","DOIUrl":"10.1016/j.retram.2025.103529","url":null,"abstract":"<div><h3>Background</h3><div>Diclofenac, a non-steroidal anti-inflammatory drug (NSAID), has demonstrated promising antitumor properties; however, its clinical application is limited by systemic toxicity. Encapsulation in biodegradable polymeric nanoparticles offers a strategy to enhance therapeutic efficacy while minimizing adverse effects. Nevertheless, the use of toxic organic solvents in nanoparticle fabrication remains a significant challenge.</div></div><div><h3>Objective</h3><div>This study aimed to develop and characterize diclofenac diethylamine-loaded polycaprolactone (PCL) nanoparticles using green solvents and to compare two preparation methods-emulsification solvent evaporation/extraction and spontaneous emulsification solvent diffusion-for producing diclofenac-loaded nanoparticles with potential applications in tumor therapy.</div></div><div><h3>Methods</h3><div>Diclofenac diethylamine-loaded PCL nanoparticles were prepared using both methods, employing a novel green solvent system. The nanoparticles were characterized in terms of size, polydispersity index (PDI), zeta potential, morphology, and encapsulation efficiency. In vitro drug release profiles were evaluated and fitted to kinetic models.</div></div><div><h3>Results</h3><div>The developed diclofenac diethylamine-loaded PCL nanoparticles exhibited a mean diameter below 200 nm, a monodisperse population, and a negative surface charge. Both preparation methods achieved high encapsulation efficiency and prolonged, diffusion-controlled drug release. The spontaneous solvent diffusion method provided slightly better control over particle size.</div></div><div><h3>Conclusion</h3><div>These nanoparticles are well-suited for cancer therapy, offering sustained drug release, enhanced safety due to the use of green solvents, and robust physicochemical stability. The findings support their potential as an innovative, effective, and safe delivery system for antitumoral applications.</div></div>","PeriodicalId":54260,"journal":{"name":"Current Research in Translational Medicine","volume":"73 4","pages":"Article 103529"},"PeriodicalIF":3.2,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144686575","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immunotherapy with ex vivo–expanded donor-derived NK cells after haploidentical HSCT in pediatric patients with AML: a phase I pilot study","authors":"Tahereh Rostami ,&nbsp;Mohammad Ahmadvand ,&nbsp;Bahram Chahardoli ,&nbsp;Mohammad Reza Rostami ,&nbsp;Mojtaba Azari ,&nbsp;Morteza Azari ,&nbsp;Azadeh Kiumarsi ,&nbsp;Ghasem Janbabaei","doi":"10.1016/j.retram.2025.103534","DOIUrl":"10.1016/j.retram.2025.103534","url":null,"abstract":"<div><h3>Background</h3><div>Post-transplant relapse remains a considerable challenge for achieving successful outcomes in pediatric patients with acute myeloid leukemia (AML) receiving haploidentical hematopoietic stem cell transplantation (HSCT). Adoptive immune cell therapy strategies utilizing highly purified donor-derived natural killer (NK) cells have been extensively explored in various transplantation settings, demonstrating promise in preventing disease recurrence, especially in pediatric AML patients.</div></div><div><h3>Methods</h3><div>Five pediatric and adolescent patients with high-risk AML were included in this pilot study and received haploidentical HSCT. On day 7 post-HSCT, all the patients received a single infusion of interleukin (IL)-2 stimulated ex vivo-expanded haploidentical NK cells (1 × 10⁶/kg CD56+ cells of patient body weight).</div></div><div><h3>Results</h3><div>All the patients tolerated the administration of NK cells without any adverse events during or after the infusion. Relapse occurred in two patients, both within the first 100 days post-transplantation, while three patients remained alive and disease-free one year post-transplantation.</div></div><div><h3>Conclusion</h3><div>This pilot study demonstrated that the activation, expansion, and infusion of NK cells from readily available haploidentical donors in pediatric and adolescent patients with high-risk AML after HSCT is safe and feasible.</div></div>","PeriodicalId":54260,"journal":{"name":"Current Research in Translational Medicine","volume":"73 4","pages":"Article 103534"},"PeriodicalIF":3.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144904040","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}